Atovaquone

Overview

Atovaquone (Atavaquone) is a potent, selective and orally active inhibitor of the parasite’s mitochondrial cytochrome bc1 complex . Atovaquone is against human and P. falciparum cytochrome bc1 activity with IC 50 values of 460 nM and 2.0 nM, respectively. Atovaquone is an antimalarial agent and has the potential for the investigation of neumocystis pneumonia, toxoplasmosis, malaria, and babesia.

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Viral Infection | Products > Disease Areas > HIV Infection | Products > Disease Areas > Bacterial Infection | Products > Disease Areas > Parasitic Infection | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Parasite | Products > Signaling Pathways > Cytochrome P450 | Products > Signaling Pathways > Antibiotic | Products > Signaling Pathways > Bacterial

Product Information

• Catalog No.: HY-13832
• CAS No.: 95233-18-4
• Molecular Formula: C22H19ClO3
• Molecular Weight: 366.84
• Purity: 99.75%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: 0.83 mg/mL (2.26 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source